Legonucleotides for detection
Chem2Sense aims to revolutionize biosensor development by creating high-affinity aptalegomers through reversible aptamer conjugation and advanced nanopore sequencing techniques.
Projectdetails
Introduction
Sensors have a vital importance on human life, detecting diseases or contaminants that endanger the environment. A widely pursued challenge has been to develop universal biosensors with the flexibility to detect molecules regardless of their size.
Challenges with Current Solutions
Antibodies have been used to fulfill this aim, but single-stranded oligonucleotides (aptamers) interact efficiently with targets and have also been proposed as an alternative. However, aptamers lack the ability for versatile functionalization to tune affinities, and they suffer from highly complex selection and identification.
Proposed Approach
Chem2Sense proposes an interdisciplinary approach to overcome these obstacles. My hypothesis is that a new strategy based on the reversible conjugation of aptamers with small molecules will remove barriers in designing universal biosensors.
Objectives of Chem2Sense
Chem2Sense aims to redesign the aptamer concept with flexible oligolegonucleotides and a cutting-edge nanopore sequencing methodology. The two objectives will be:
- To develop chemically modified nucleotides as lego-bricks to build high-affinity aptalegomers.
- To develop a ground-breaking sequencing methodology using artificial intelligence to boost aptalegomer identification.
Methodology
The proposed legonucleotides are synthetic nucleotides that reversibly attach small molecules in a dynamic combinatorial library. After challenging a vast library against a target, a Darwinian chemical selection will occur, leading to the best fit, the aptalegomer, a high-affinity oligonucleotide of natural and conjugated legonucleotides.
Conclusion
Therefore, the objective of Chem2Sense is to create a ground-breaking methodology that overcomes significant obstacles in aptamers development, providing a powerful synergy between novel chemical aptalegomers generation and a direct method for selection/identification using the latest advances in oligonucleotide sequencing. Chem2Sense will bring highly sensitive and versatile aptalegomers to a broad range of vital applications.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.999.144 |
Totale projectbegroting | € 1.999.144 |
Tijdlijn
Startdatum | 1-9-2024 |
Einddatum | 31-8-2029 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICASpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Development of Suprasensors and Assays for Molecular DiagnosticsSupraSense aims to develop advanced biomimetic sensors for detecting metabolites in biofluids, enhancing diagnostic selectivity and sensitivity for early disease detection. | ERC Consolid... | € 1.994.069 | 2023 | Details |
Biosensing by Sequence-based Activity InferenceThis project aims to develop a data-driven pipeline for engineering genetically encoded biosensors to enhance molecule detection and support sustainable bioprocesses in synthetic biology. | ERC Starting... | € 1.499.453 | 2024 | Details |
High throughput development platform for oligonucleotide aptamersSPARXS is an innovative platform that enables rapid design of affinity probes by simultaneously analyzing binding kinetics and sequences of millions of aptamers for diverse applications. | ERC Proof of... | € 150.000 | 2024 | Details |
Novel ApameR-Based Rapid Test Technology for Virus DetectionDeveloping a cost-effective RNA aptamer-based sensor for rapid point-of-care testing of avian influenza, meeting WHO ASSURED criteria, to enhance pathogen detection and containment. | ERC Proof of... | € 150.000 | 2023 | Details |
Protein function regulation through inserts for response to biological, chemical and physical signalsThis project aims to develop a modular platform for engineering proteins to sense and respond to diverse signals, enhancing their functionality for innovative biomedical applications. | ERC Advanced... | € 2.500.000 | 2024 | Details |
Development of Suprasensors and Assays for Molecular Diagnostics
SupraSense aims to develop advanced biomimetic sensors for detecting metabolites in biofluids, enhancing diagnostic selectivity and sensitivity for early disease detection.
Biosensing by Sequence-based Activity Inference
This project aims to develop a data-driven pipeline for engineering genetically encoded biosensors to enhance molecule detection and support sustainable bioprocesses in synthetic biology.
High throughput development platform for oligonucleotide aptamers
SPARXS is an innovative platform that enables rapid design of affinity probes by simultaneously analyzing binding kinetics and sequences of millions of aptamers for diverse applications.
Novel ApameR-Based Rapid Test Technology for Virus Detection
Developing a cost-effective RNA aptamer-based sensor for rapid point-of-care testing of avian influenza, meeting WHO ASSURED criteria, to enhance pathogen detection and containment.
Protein function regulation through inserts for response to biological, chemical and physical signals
This project aims to develop a modular platform for engineering proteins to sense and respond to diverse signals, enhancing their functionality for innovative biomedical applications.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Computation driven development of novel vivo-like-DNA-nanotransducers for biomolecules structure identificationThis project aims to develop DNA-nanotransducers for real-time detection and analysis of conformational changes in biomolecules, enhancing understanding of molecular dynamics and aiding drug discovery. | EIC Pathfinder | € 3.000.418 | 2022 | Details |
integrated nano-photonic OMICs bio-SENSor for lung cancerOMICSENS aims to develop a novel nano-photonic omics bio-sensor for real-time detection of TKI resistance in NSCLC, enhancing prognosis and paving the way for personalized cancer treatment. | EIC Pathfinder | € 2.372.318 | 2024 | Details |
Versatile Amplification Method for Single-Molecule Detection in Liquid BiopsyVerSiLiB aims to develop an enzyme-free amplification platform for detecting proteins and nucleic acids in liquid biopsies, enhancing cancer management through novel affinity-mediated transport. | EIC Pathfinder | € 2.994.244 | 2022 | Details |
Universal GPCR Activity Sensor for Next Generation Drug DiscoveryThis project aims to develop a novel single-assay technology platform for GPCR drug discovery, enhancing detection and classification of drug candidates to improve efficacy and reduce failures. | EIC Pathfinder | € 2.965.384 | 2023 | Details |
Transforming Molecular Diagnostics through NanoTechnologyAltratech Ltd aims to revolutionize molecular diagnostics by using patented nanotechnology for rapid, non-clinical detection of viruses and pathogens without biological amplification. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Computation driven development of novel vivo-like-DNA-nanotransducers for biomolecules structure identification
This project aims to develop DNA-nanotransducers for real-time detection and analysis of conformational changes in biomolecules, enhancing understanding of molecular dynamics and aiding drug discovery.
integrated nano-photonic OMICs bio-SENSor for lung cancer
OMICSENS aims to develop a novel nano-photonic omics bio-sensor for real-time detection of TKI resistance in NSCLC, enhancing prognosis and paving the way for personalized cancer treatment.
Versatile Amplification Method for Single-Molecule Detection in Liquid Biopsy
VerSiLiB aims to develop an enzyme-free amplification platform for detecting proteins and nucleic acids in liquid biopsies, enhancing cancer management through novel affinity-mediated transport.
Universal GPCR Activity Sensor for Next Generation Drug Discovery
This project aims to develop a novel single-assay technology platform for GPCR drug discovery, enhancing detection and classification of drug candidates to improve efficacy and reduce failures.
Transforming Molecular Diagnostics through NanoTechnology
Altratech Ltd aims to revolutionize molecular diagnostics by using patented nanotechnology for rapid, non-clinical detection of viruses and pathogens without biological amplification.